Cargando…
Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment
Human pancreatic cancer has a very poor prognosis with an overall five-year survival rate of less than 5% and an average median survival time of six months. This is largely due to metastatic disease, which is already present in the majority of patients when diagnosed. Although our understanding of t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486024/ https://www.ncbi.nlm.nih.gov/pubmed/28587243 http://dx.doi.org/10.3390/ijms18061201 |
_version_ | 1783246182252806144 |
---|---|
author | Lu, Shuangshuang Ahmed, Tasqeen Du, Pan Wang, Yaohe |
author_facet | Lu, Shuangshuang Ahmed, Tasqeen Du, Pan Wang, Yaohe |
author_sort | Lu, Shuangshuang |
collection | PubMed |
description | Human pancreatic cancer has a very poor prognosis with an overall five-year survival rate of less than 5% and an average median survival time of six months. This is largely due to metastatic disease, which is already present in the majority of patients when diagnosed. Although our understanding of the molecular events underlying multi-step carcinogenesis in pancreatic cancer has steadily increased, translation into more effective therapeutic approaches has been inefficient in recent decades. Therefore, it is imperative that novel and targeted approaches are designed to facilitate the early detection and treatment of pancreatic cancer. Presently, there are numerous ongoing studies investigating the types of genomic variations in pancreatic cancer and their impact on tumor initiation and growth, as well as prognosis. This has led to the development of therapeutics to target these genetic variations for clinical benefit. Thus far, there have been minimal clinical successes directly targeting these genomic alterations; however research is ongoing to ultimately discover an innovative approach to tackle this devastating disease. This review will discuss the genomic variations in pancreatic cancer, and the resulting potential diagnostic and therapeutic implications. |
format | Online Article Text |
id | pubmed-5486024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54860242017-06-29 Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment Lu, Shuangshuang Ahmed, Tasqeen Du, Pan Wang, Yaohe Int J Mol Sci Review Human pancreatic cancer has a very poor prognosis with an overall five-year survival rate of less than 5% and an average median survival time of six months. This is largely due to metastatic disease, which is already present in the majority of patients when diagnosed. Although our understanding of the molecular events underlying multi-step carcinogenesis in pancreatic cancer has steadily increased, translation into more effective therapeutic approaches has been inefficient in recent decades. Therefore, it is imperative that novel and targeted approaches are designed to facilitate the early detection and treatment of pancreatic cancer. Presently, there are numerous ongoing studies investigating the types of genomic variations in pancreatic cancer and their impact on tumor initiation and growth, as well as prognosis. This has led to the development of therapeutics to target these genetic variations for clinical benefit. Thus far, there have been minimal clinical successes directly targeting these genomic alterations; however research is ongoing to ultimately discover an innovative approach to tackle this devastating disease. This review will discuss the genomic variations in pancreatic cancer, and the resulting potential diagnostic and therapeutic implications. MDPI 2017-06-05 /pmc/articles/PMC5486024/ /pubmed/28587243 http://dx.doi.org/10.3390/ijms18061201 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lu, Shuangshuang Ahmed, Tasqeen Du, Pan Wang, Yaohe Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title_full | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title_fullStr | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title_full_unstemmed | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title_short | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment |
title_sort | genomic variations in pancreatic cancer and potential opportunities for development of new approaches for diagnosis and treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486024/ https://www.ncbi.nlm.nih.gov/pubmed/28587243 http://dx.doi.org/10.3390/ijms18061201 |
work_keys_str_mv | AT lushuangshuang genomicvariationsinpancreaticcancerandpotentialopportunitiesfordevelopmentofnewapproachesfordiagnosisandtreatment AT ahmedtasqeen genomicvariationsinpancreaticcancerandpotentialopportunitiesfordevelopmentofnewapproachesfordiagnosisandtreatment AT dupan genomicvariationsinpancreaticcancerandpotentialopportunitiesfordevelopmentofnewapproachesfordiagnosisandtreatment AT wangyaohe genomicvariationsinpancreaticcancerandpotentialopportunitiesfordevelopmentofnewapproachesfordiagnosisandtreatment |